Performance of the continuous glucose monitoring system (CGMS) during development of ketosis in patients on insulin pump therapy
- 14 September 2006
- journal article
- Published by Wiley in Diabetic Medicine
- Vol. 23 (10), 1124-1129
- https://doi.org/10.1111/j.1464-5491.2006.01945.x
Abstract
Aims Ketoacidosis is one of the most severe complications of Type 1 diabetes. Development of ketosis leads to substantial shifts in electrolyte and ion concentrations in the different fluid compartments of the body. This study was performed to investigate the performance of the continuous glucose monitoring device (CGMS) during ketoacidosis. Methods Twelve patients with Type 1 diabetes using continuous subcutaneous insulin infusion (CSII) participated in this trial [10 women, two men; age (mean ± sd) 34 ± 9 years; disease duration 17 ± 10 years; HbA1c 7.1 ± 1.0%]. In the morning, patients ate breakfast and the insulin pump was stopped at 11.00 h and restarted after 8 h. Observation parameters during this experiment were: blood glucose (laboratory reference and CGMS), 3‐hydroxy‐butyrate (3‐OHB), pH, Na, pCO2, pO2, free fatty acids, osmolarity, standard bicarbonate, and lactate. Results Blood glucose increased and reached a plateau within 2 h after pump stop (from 6.2 ± 2.56 to 16.7 ± 4.44 mmol/l, P < 0.001). A constant increase in 3‐OHB (from 0.0 to 0.8 ± 0.5 mmol/l, P < 0.001) and decrease in pH (from 7.43 ± 0.02 to 7.40 ± 0.03, P < 0.05) indicated ketosis development. Na decreased from 141 ± 1.4 to 138 ± 2.8 mmol/l, P < 0.001). Free fatty acids increased from 0.577 ± 0.330 to 1.330 ± 0.462 mmol/l (P < 0.001). The CGMS values showed excellent agreement with the capillary blood laboratory method during the entire experiment, and a modified error grid analysis revealed that 99.5% of the values were in the clinically acceptable zones A and B. Conclusion The CGMS device was confirmed to be reliable and accurate during the development of hyperglycaemia and ketotic conditions.Keywords
This publication has 24 references indexed in Scilit:
- Reproducibility and reliability of hypoglycaemic episodes recorded with Continuous Glucose Monitoring System (CGMS) in daily lifeDiabetic Medicine, 2005
- Optimization of basal insulin delivery in Type 1 diabetes: a retrospective study on the use of continuous subcutaneous insulin infusion and insulin glargineDiabetic Medicine, 2005
- Experience with the Continuous Glucose Monitoring System® in a Medical Intensive Care UnitDiabetes Technology & Therapeutics, 2004
- Continuous subcutaneous insulin infusion with short‐acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost‐effectivenessDiabetes/Metabolism Research and Reviews, 2004
- Assessment of hypoglycaemia awareness using continuous glucose monitoringDiabetic Medicine, 2004
- The Importance of Continuous Glucose Monitoring in DiabetesDiabetes Technology & Therapeutics, 2000
- Comparison of Metabolic Deterioration between Insulin Analog and Regular Insulin after a 5-Hour Interruption of a Continuous Subcutaneous Insulin Infusion in Type 1 Diabetic PatientsJournal of Clinical Endocrinology & Metabolism, 1999
- Cessation of insulin infusion at night-time during CSII-therapy: Comparison of regular human insulin and insulin lisproExperimental and Clinical Endocrinology & Diabetes, 1998
- Hyperglycemic crises in urban blacksArchives of Internal Medicine, 1997
- Evaluating Clinical Accuracy of Systems for Self-Monitoring of Blood GlucoseDiabetes Care, 1987